Brief: Histogen And Amerimmune Announce Positive Top-Line Study Results From Its Phase 1 Study Of Emricasan In Mild Symptomatic Covid-19 Patients

Histogen

22/06/2021 13:30

June 22 (Reuters) - Amerimmune Pharmaceuticals Inc
 AMMMM.UL :
    * HISTOGEN AND AMERIMMUNE ANNOUNCE POSITIVE TOP-LINE STUDY
RESULTS
FROM ITS PHASE 1 STUDY OF EMRICASAN IN MILD SYMPTOMATIC COVID-19
PATIENTS
    * HISTOGEN INC - EMRICASAN FOUND TO BE SAFE AND WELL
TOLERATED
WITH NO SERIOUS ADVERSE EVENTS
    * HISTOGEN -PATIENTS COMPLETING EMRICASAN TREATMENT HAD
COMPLETE
RESOLUTION OF SYMPTOMS COMMONLY ASSOCIATED IN MILD COVID-19 AT
DAY 7 CONTINUING TO DAY 45

Source text for Eikon:  ID:nGNX3TztVZ 
Further company coverage:  AMMMM.UL 

 ((Reuters.Briefs@thomsonreuters.com;))